# US Malaria Diagnostics Market

> US Malaria Diagnostics Market Research Report: Size, Share, Trend Analysis By Technology (Rapid Diagnostic Tests, Microscopy, Polymerase Chain Reaction, Serology Tests, Loop-Mediated Isothermal Amplification), By End Users (Hospitals, Diagnostic Laboratories, Research Institutes, Home Care Settings), By Product Type (Test Kits, Reagents, Instruments) and By Applications (Clinical Diagnosis, Epidemiological Studies, Drug Efficacy Studies) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.23%
- **2024:** $ 7.05 Million
- **2025:** $ 7.49 Million
- **2035:** $ 13.71 Million
- **Key Players:** Roche (CH), Abbott (US), Siemens Healthineers (DE), BD (US), Cepheid (US), Hologic (US), Thermo Fisher Scientific (US), Diatheva (IT)

**Report ID:** MRFR/LS/13113-HCR · **Pages:** 100 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-malaria-diagnostics-market-14640

---

## Market Summary

## **US Malaria Diagnostics Market Overview**

As per MRFR analysis, the US Malaria Diagnostics Market Size was estimated at 690.9 (USD Million) in 2023. The US Malaria Diagnostics Market Industry is expected to grow from 750(USD Million) in 2024 to 1,450 (USD Million) by 2035. The US Malaria Diagnostics Market CAGR (growth rate) is expected to be around 6.176% during the forecast period (2025 - 2035).

### **Key US Malaria Diagnostics Market Trends Highlighted**

The US Malaria Diagnostics Market is seeing a significant shift driven by the need for rapid and accurate diagnosis of malaria, particularly due to occasional outbreaks and the presence of malaria in travelers returning from endemic regions. Key market drivers include increasing awareness about malaria prevention and control measures supported by government agencies like the Centers for Disease Control and Prevention (CDC) and the promotion of robust surveillance systems.

With the US government investing in research and development for new diagnostic technologies, such as molecular diagnostics and rapid diagnostic tests (RDTs), there are ample opportunities for innovation and advancement in this sector.

Recent trends show an uptick in the adoption of point-of-care testing, which allows for immediate diagnosis and treatment, thereby improving patient outcomes. The emphasis on improving accessibility to diagnostics in remote and underserved areas is also gaining traction, as it aligns with national public health initiatives. Furthermore, collaborations between public health organizations and private entities are fostering advancements in malaria diagnostics, exploring innovations like smartphone-based diagnostic tools that could streamline testing processes. Additionally, the growing emphasis on personalized medicine presents opportunities for tailoring malaria diagnostics to individual patients' needs.

As the demand for effective malaria control strategies continues to rise, the US Malaria Diagnostics Market is poised for growth driven by cutting-edge technologies and an increased focus on preventive healthcare measures.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **US Malaria Diagnostics Market Drivers**

#### **Increase in Travel-Related Malaria Cases**

The increase in international travel from the United States to malaria-endemic regions is a major driver for the US Malaria Diagnostics Market Industry. The Centers for Disease Control and Prevention (CDC) reported that malaria cases in the United States have been rising, from an average of about 1,700 cases annually in recent years to approximately 2,000 cases in 2022, largely due to travelers returning from regions in Africa and Southeast Asia where malaria is prevalent.

This uptick necessitates advanced and reliable malaria diagnostic tools, resulting in increased investment by manufacturers and healthcare providers in the United States. Organizations like Abbott Laboratories and Siemens Healthineers are continuously innovating their diagnostic technologies to meet the growing demand for efficient malaria testing among returning travelers, thereby propelling market growth.

#### **Advancements in Diagnostic Technologies**

Innovative technologies in malaria diagnostics, such as rapid diagnostic tests (RDTs) and polymerase chain reaction (PCR) techniques, are significantly enhancing the accuracy and speed of malaria detection in the US Malaria Diagnostics Market Industry. The adoption of these advanced diagnostic methods is critical especially in the context of combating infectious diseases. A study published in the journal Malaria Journal mentioned that the introduction of RDTs increased the detection rate of malaria cases by up to 90% in some testing scenarios.

Companies like Roche Diagnostics and Bio-Rad Laboratories are leading the charge in developing high-precision diagnostic tools, making it easier to diagnose malaria swiftly and accurately, which boosts market potential as healthcare centers adopt these technologies.

#### **Government Initiatives and Funding**

The role of government initiatives and funding in fighting malaria is an essential driver in the US Malaria Diagnostics Market Industry. Public Health Agencies in the United States have been increasingly allocating resources toward malaria control measures, as outlined in various strategic plans, including the National Malaria Control Strategy. In recent years, the National Institute of Health has increased funding for Research and Development projects focusing on malaria diagnostics, allocating millions to facilitate innovative testing methods and awareness programs aimed at mitigating malaria cases.

This financial support enhances the capacity of healthcare providers to utilize advanced diagnostic tools, further driving growth in the market.

## **US Malaria Diagnostics Market Segment Insights**

### **Malaria Diagnostics Market Technology Insights**

The Technology segment of the US Malaria Diagnostics Market has evolved significantly, enhancing the detection and diagnosis of malaria. Rapid Diagnostic Tests (RDTs) emerge as a crucial technology in this segment due to their ability to provide quick results, which is vital in clinical settings and can substantially improve patient management. RDTs have gained prominence in point-of-care testing, making them particularly useful in remote and resource-limited areas where laboratory access is limited. On the other hand, Microscopy remains a foundational technology, especially in more established healthcare facilities.

This technique relies on examining blood smears, providing not only the diagnosis but also the ability to assess the level of parasitemia, which is crucial for treatment decisions.

Polymerase Chain Reaction (PCR) technology offers a higher sensitivity and specificity compared to traditional methods, making it increasingly important for accurately diagnosing malaria in low-prevalence settings. The precision of PCR allows for identification at the species level, aiding in tailored treatment protocols, thus helping to combat antimalarial resistance, a growing challenge in the field. Serology Tests are also significant as they enable the detection of malaria exposure through antibody detection, which assists in epidemiological studies and surveillance programs.

Additionally, Loop-Mediated Isothermal Amplification (LAMP) has emerged as a noteworthy method, being both rapid and cost-effective, making it more accessible for widespread testing. This method is showing promise in delivering reliable results without the need for sophisticated laboratory infrastructure, which further broadens the scope in diagnosing malaria. The convergence of these technologies within the US Malaria Diagnostics Market illustrates a versatile landscape that caters to various needs across healthcare settings, contributing to improved public health outcomes.

As malaria continues to be a public health concern, the advancements in these diagnostic technologies will play a pivotal role in enhancing disease management and prevention strategies across the nation. These factors collectively point to a robust landscape in the US Malaria Diagnostics Market, where diverse technologies contribute to more effective health interventions.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Malaria Diagnostics Market End User Insights**

The US Malaria Diagnostics Market is significantly influenced by various end users, which play a vital role in managing and diagnosing malaria effectively. Hospitals serve as primary facilities where a substantial number of diagnoses occur, offering advanced technologies and immediate medical interventions for patients. Diagnostic Laboratories are crucial in the market as they possess the specialized equipment and expertise needed to accurately identify malaria, thereby ensuring timely treatment. Research Institutes contribute significantly to the advancement of malaria diagnostics by developing new methods and technologies to enhance detection and treatment efficacy.

Additionally, Home Care Settings are gaining traction as they provide convenient diagnostic options for patients in remote areas or those seeking immediate testing without visiting healthcare facilities. With an increasing emphasis on early detection and response to malaria, the demand across these end user sectors is expected to grow, reflecting the importance of targeted strategies in combating malaria. The overall landscape underscores the vital role that each segment plays in the fight against this infectious disease, shaping the future of malaria diagnostics in the US.

### **Malaria Diagnostics Market Product Type Insights**

The US Malaria Diagnostics Market is characterized by its diverse Product Type segment, which includes Test Kits, Reagents, and Instruments. Test Kits are essential for rapid diagnosis, making them significant for timely treatment and disease management, thereby supporting public health initiatives. In contrast, Reagents play a crucial role in laboratory settings, enabling accurate detection through various diagnostic methodologies, which aids in confirming malaria cases. Instruments, including advanced diagnostic devices, contribute to a more efficient diagnostic process, ensuring reliability in results.

This segment is vital as it supports both clinical settings and research activities aimed at malaria control and eradication. The increasing prevalence of malaria, along with the need for prompt diagnosis in endemic regions of the US, underscores the importance of these Product Types in the overall landscape of the US Malaria Diagnostics Market, highlighting trends such as the development of innovative technologies and accuracy improvements in malarial testing.

### **Malaria Diagnostics Market Application Insights**

The US Malaria Diagnostics Market focuses on various applications crucial for effective disease management. Clinical diagnosis plays a vital role, as it ensures timely and accurate identification of malaria, which is essential for appropriate treatment. This aspect significantly contributes to reducing mortality rates associated with the disease. Epidemiological studies are crucial for understanding the prevalence, distribution, and dynamics of malaria transmission within the population, providing data that inform public health strategies.

These studies support targeted interventions and resource allocation. Additionally, drug efficacy studies are essential for evaluating the effectiveness of new and existing treatments against malaria, ensuring that healthcare providers can offer the most effective care options. The significance of these applications lies in their combined efforts to control and eliminate malaria, a critical public health concern in the United States. Overall, the US Malaria Diagnostics Market segmentation reflects a comprehensive approach to tackling malaria through diverse and impactful applications.

## **US Malaria Diagnostics Market Key Players and Competitive Insights**

The US Malaria Diagnostics Market has been witnessing significant developments driven by increasing awareness about malaria's prevalence and the necessity for timely diagnosis and treatment. The market is characterized by the presence of various players, each striving to innovate and improve diagnostic accuracy. Factors such as advancements in technology, regulatory approvals for rapid diagnostic tests, and the integration of artificial intelligence in diagnostic processes have revolutionized the landscape. Competitive insights in this market reveal a dynamic interaction among established companies, promising start-ups, and research institutions, all aiming to enhance diagnostic capabilities and address the evolving needs of healthcare providers.

The need for effective malaria diagnostics has intensified due to the ongoing efforts to eliminate malaria in specific regions, creating a conducive environment for market players to thrive.

Hologic has carved a unique niche within the US Malaria Diagnostics Market through its commitment to advancing women's health and infectious disease diagnostics. The company leverages innovative technologies to develop state-of-the-art diagnostic solutions that ensure accurate and rapid results. Hologic's strengths lie in its extensive research and development capabilities, allowing it to stay at the forefront of diagnostic innovation. The company's expertise in molecular diagnostics and its comprehensive portfolio help it maintain a competitive edge in this market.

Hologic's strategic focus on partnerships with healthcare providers and its presence in various diagnostic platforms underscore its commitment to enhancing malaria diagnostic capabilities in the United States. The company’s commitment to quality and accuracy has positioned it as a trusted player among healthcare professionals, contributing significantly to the overall efficiency of malaria management within the US.

Genzyme operates within the US Malaria Diagnostics Market, where it is recognized for its robust portfolio of diagnostic solutions tailored to the needs of clinicians and laboratories. The company emphasizes the development of high-quality tests that provide reliable results for effective malaria management. Genzyme stands out due to its strong market presence, bolstered by its strategic acquisitions that have expanded its capabilities and breadth in diagnostics. The company focuses on delivering a range of diagnostic products, including rapid tests and laboratory-based solutions. Its strengths lie in advanced technological integration and a strong commitment to research and development.

Genzyme is also committed to enhancing healthcare access through collaborations with local health authorities and organizations to combat malaria effectively. The company's proactive approach in addressing market demands, along with its continuous efforts to innovate, ensures its significant impact on malaria diagnostics in the US, positioning it as a key player in tackling this pressing public health issue.

### **Key Companies in the US Malaria Diagnostics Market Include**

- Hologic
- Genzyme
- BioRad Laboratories
- Grifols
- Danaher
- F. HoffmannLa Roche
- Thermo Fisher Scientific
- Cepheid
- Meridian Bioscience
- Quidel
- Roche
- **[Abbott](https://www.abbott.com/product-list.html)**
- Siemens
- BD

## **US Malaria Diagnostics Market Industry Developments**

The US [Malaria Diagnostics](../../../reports/malaria-diagnostics-market-6432) Market has seen significant developments recently, with companies like Hologic and Thermo Fisher Scientific focusing on enhancing their diagnostic capabilities amidst a rise in malaria cases linked to climate factors. In September 2023, Abbott launched a rapid malaria test aimed at improving detection rates in endemic regions within the US. Growth in market valuation is evident, as evidenced by Danaher's acquisition strategy aimed at broadening its diagnostic portfolio through innovations.

Grifols and BioRad Laboratories are exploring partnerships to enhance their diagnostics solutions, reflecting a trend toward collaborative efforts in technology advancement. Additionally, in July 2023, Roche announced the launch of a new diagnostic platform that enhances sensitivity and specificity for malaria detection. Furthermore, Meridian Bioscience reported a steady rise in revenue during 2022 due to increased demand for malaria diagnostic tests.

Current affairs also reflect a heightened emphasis on R&D investments targeted at malaria diagnostics, with agencies such as the Centers for Disease Control and Prevention emphasizing the need for more robust testing solutions in response to rising global malaria cases. These trends depict an evolving market landscape, driven by innovations and strategic collaborations among major companies.

## **US Malaria Diagnostics Market Segmentation Insights**

### **Malaria Diagnostics Market Technology Outlook**

- Rapid Diagnostic Tests
- Microscopy
- Polymerase Chain Reaction
- Serology Tests
- Loop-Mediated Isothermal Amplification

### **Malaria Diagnostics Market End User Outlook**

- Hospitals
- Diagnostic Laboratories
- Research Institutes
- Home Care Settings

### **Malaria Diagnostics Market Product Type Outlook**

- Test Kits
- Reagents
- Instruments

### **Malaria Diagnostics Market Application Outlook**

- Clinical Diagnosis
- Epidemiological Studies
- Drug Efficacy Studies

## Market Drivers

### Rising Incidence of Malaria Cases

The rising incidence of malaria cases in certain regions is a significant driver for the malaria diagnostics market. Although the US has made considerable progress in controlling malaria, sporadic outbreaks still occur, necessitating effective diagnostic tools. the malaria diagnostics market is projected to experience growth as healthcare providers respond to these outbreaks by increasing testing capabilities.. According to the Centers for Disease Control and Prevention (CDC), there were approximately 2,000 reported cases of malaria in the US in recent years, underscoring the need for reliable diagnostic methods. This trend may prompt healthcare systems to invest more in malaria diagnostics, thereby expanding the market.

### Government Initiatives and Funding

Government initiatives and funding play a pivotal role in shaping the malaria diagnostics market. In the US, various federal and state programs aim to combat malaria through improved diagnostic capabilities. Increased funding for research and development in malaria diagnostics has led to the emergence of innovative testing methods. For instance, the National Institutes of Health (NIH) has allocated substantial resources to support studies focused on malaria detection technologies. This financial backing is expected to drive growth in the malaria diagnostics market, as it encourages collaboration between public health organizations and private sector companies to develop effective diagnostic solutions.

### Growing Awareness of Malaria Risks

The increasing awareness of malaria risks among the population is a crucial driver for the malaria diagnostics market. Educational campaigns and public health initiatives have highlighted the dangers of malaria, particularly in regions where the disease is endemic. This heightened awareness has led to a greater demand for effective diagnostic tools, as individuals and healthcare providers seek to identify and treat malaria cases promptly. In the US, over the next five years., driven by this awareness. As more people understand the importance of early detection, the market for malaria diagnostics is likely to expand, fostering innovation and the development of new diagnostic technologies.

### Increased Focus on Global Health Security

The increased focus on The malaria diagnostics market. As the world becomes more interconnected, the potential for malaria to spread beyond endemic regions has raised concerns among public health officials. This has led to a greater emphasis on surveillance and early detection of malaria cases. the malaria diagnostics market is projected to benefit from this trend., as governments and health organizations prioritize investments in diagnostic technologies to enhance preparedness. The commitment to global health security may result in collaborative efforts to develop and distribute advanced diagnostic tools, ultimately strengthening the malaria diagnostics market.

### Technological Advancements in Diagnostic Tools

Technological advancements in diagnostic tools are significantly influencing the malaria diagnostics market. Innovations such as rapid diagnostic tests (RDTs) and molecular techniques have improved the accuracy and speed of malaria detection. These advancements enable healthcare providers to diagnose malaria more efficiently, which is essential for effective treatment. the malaria diagnostics market is projected to reach a valuation of $1.5 billion by 2027., largely due to these technological improvements. Furthermore, the integration of digital health solutions, such as mobile applications for data collection and analysis, is likely to enhance the overall diagnostic process, making it more accessible and user-friendly.

## Future Outlook

The [Malaria Diagnostics Market](https://www.marketresearchfuture.com/reports/malaria-diagnostics-market-6432) is projected to grow at a 6.23% CAGR from 2025 to 2035, driven by technological advancements, increased funding, and rising awareness.

**New opportunities:**

- Development of rapid diagnostic test kits for remote areas.
- Integration of AI for predictive analytics in diagnostics.
- Expansion of telemedicine platforms for remote consultations.

By 2035, the market is expected to achieve substantial growth, enhancing diagnostic capabilities and accessibility.

## Segment Insights

### By Technology: Rapid Diagnostic Tests (Largest) vs. Polymerase Chain Reaction (Fastest-Growing)

In the US malaria diagnostics market, Rapid Diagnostic Tests (RDTs) dominate the landscape, holding a significant market share due to their ease of use and quick results. Microscopy and Serology Tests follow, with RDTs accounting for a large portion of malaria diagnostics, favored for their comprehensive applications in low-resource settings. Meanwhile, Polymerase Chain Reaction (PCR) is gaining traction, representing a growing interest for its high sensitivity and specificity, with the other technologies integrating to create a multifaceted approach to diagnosis.

Growth trends in this segment illustrate a shift towards more advanced technologies. PCR is rapidly emerging as the fastest-growing method, driven by rising demand for accurate and fast diagnostic tools in response to prevention and treatment efforts. As healthcare providers seek to enhance their diagnostic capabilities, investments in RDTs continue, supported by favorable reimbursement policies. The increasing focus on integration of innovative technologies to improve malaria diagnosis reflects broader trends in healthcare and technology.

Technology: RDTs (Dominant) vs. PCR (Emerging)

Rapid Diagnostic Tests (RDTs) are characterized by their user-friendly design and speed, allowing for immediate diagnosis, which is particularly crucial in malaria management. They are widely adopted in various healthcare settings, from urban hospitals to remote clinics. In contrast, Polymerase Chain Reaction (PCR) is an emerging technology that offers advanced detection capabilities, particularly for low-parasite-density infections. PCR's ability to provide precise and reliable results positions it as a preferred choice for specialized laboratories. As the US malaria diagnostics market evolves, both RDTs and PCR will play significant roles, catering to diverse requirements, from routine screening to complex diagnostic scenarios.

### By End User: Hospitals (Largest) vs. Diagnostic Laboratories (Fastest-Growing)

In the US malaria diagnostics market, hospitals dominate the end user segment, capturing a significant share due to their substantial resources and the critical need for timely diagnostics. Diagnostic laboratories follow closely, representing a vital resource for pathogen identification and analysis. Research institutes and home care settings, while smaller in market share, play essential roles in advancing research and improving accessibility to diagnostics.

The growth trends for the end user segment are driven by advancements in diagnostic technologies, increased awareness of malaria, and rising government initiatives to enhance healthcare infrastructure. Hospitals are expected to remain dominant due to their integrated approach to patient care. Meanwhile, diagnostic laboratories are the fastest-growing segment, fueled by the demand for rapid and accurate testing methods, particularly in outbreak situations.

Hospitals (Dominant) vs. Diagnostic Laboratories (Emerging)

Hospitals are the dominant end users in the malaria diagnostics arena, primarily due to their critical role in patient care and comprehensive diagnostic services. Equipped with advanced technology, they can provide timely and accurate diagnoses. Their ability to integrate various medical services enhances their position within the market. On the other hand, diagnostic laboratories are emerging as a crucial player in the market landscape. They focus on specialized testing and analysis, catering to both hospitals and direct consumers. The growing prevalence of malaria concerns and the need for efficient diagnostics is propelling laboratories to innovate and expand their services, establishing themselves as a key component in combating malaria effectively.

### By Product Type: Test Kits (Largest) vs. Reagents (Fastest-Growing)

In the US malaria diagnostics market, the distribution of market share among product types reveals that test kits dominate the landscape, capturing the majority of market interest and sales. Their widespread acceptance is due to user-friendly features and rapid diagnostic capabilities. In contrast, reagents hold a smaller share; however, their importance cannot be underestimated as they are essential for performing tests, thereby facilitating the operations of laboratories and healthcare facilities.

Growth trends in this segment are primarily driven by advancements in diagnostic technologies and an increase in malaria cases in certain regions. The demand for rapid testing solutions has significantly bolstered the test kits market, while the reagents segment is experiencing fast-paced growth as healthcare providers seek reliable components for effective diagnostics. This overall trend indicates a robust future for both segments in the evolving landscape of malaria diagnostics.

Test Kits (Dominant) vs. Reagents (Emerging)

Test kits in the US malaria diagnostics market are characterized by their convenience, speed, and reliability, making them the preferred choice for rapid detection of malaria. Their dominant market position is attributed to their ease of use and minimal need for specialized training, allowing for widespread application in clinics and remote settings. On the other hand, reagents are emerging as crucial components in the diagnostics process, with growing attention to their quality and effectiveness. As laboratories increasingly rely on sophisticated tests, the demand for quality reagents is rising, indicating a shift towards the optimization of diagnostic accuracy. This duality between dominant test kits and emerging reagents highlights the interdependence within the market.

### By Application: Clinical Diagnosis (Largest) vs. Epidemiological Studies (Fastest-Growing)

In the US malaria diagnostics market, Clinical Diagnosis holds the largest share, driven by its critical role in the immediate detection and treatment of malaria cases. Epidemiological Studies, while currently smaller in market share, are rapidly growing as public health initiatives increasingly focus on surveillance and control of malaria outbreaks, highlighting the importance of this segment in broader health strategies.

Growth in the US malaria diagnostics market is largely influenced by advancements in diagnostic technology and increasing awareness of malaria's public health impact. The rising demand for efficient and quick diagnostic methods supports the Clinical Diagnosis segment's dominance, whereas the growing funding for research and development is propelling Epidemiological Studies as the fastest-growing segment, reflecting a shift towards proactive malaria management and prevention strategies.

Clinical Diagnosis: Dominant vs. Epidemiological Studies: Emerging

Clinical Diagnosis remains the dominant segment within the US malaria diagnostics market due to its established infrastructure and essential role in patient care. The segment benefits from a wide range of diagnostic tests that provide quick results, aiding in timely treatment decisions. On the other hand, Epidemiological Studies represent an emerging segment focusing on the collection and analysis of data to track malaria transmission patterns. This segment is characterized by partnerships between governmental and non-governmental organizations to enhance surveillance systems and improve public health responses, marking a significant shift towards data-driven malaria management.

## Competitive Benchmarking

The malaria diagnostics market is currently characterized by a dynamic competitive landscape, driven by a confluence of technological advancements, increasing awareness of malaria's impact, and a growing emphasis on rapid and accurate diagnostics. Key players such as Roche (CH), Abbott (US), and BD (US) are strategically positioned to leverage their extensive research capabilities and established market presence. Roche (CH) focuses on innovation in molecular diagnostics, while Abbott (US) emphasizes the integration of digital health solutions into its diagnostic platforms. BD (US) is enhancing its operational focus on point-of-care testing, which is crucial for timely malaria detection. Collectively, these strategies not only enhance their competitive edge but also contribute to a more robust market environment.In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and improve supply chain efficiency. This approach appears to be particularly relevant in the context of the malaria diagnostics market, which is moderately fragmented, with several players vying for market share. The collective influence of these key players is shaping a competitive structure that encourages innovation and responsiveness to market demands, thereby fostering a more resilient supply chain.

In October  Abbott (US) announced a partnership with a leading telehealth provider to enhance remote diagnostic capabilities for malaria. This strategic move is significant as it aligns with the growing trend of digital health integration, allowing for quicker diagnosis and treatment recommendations, particularly in remote areas where access to healthcare is limited. Such partnerships may enhance Abbott's market position by expanding its reach and improving patient outcomes.

In September  Roche (CH) launched a new rapid diagnostic test that utilizes advanced molecular techniques to detect malaria with higher sensitivity and specificity. This innovation is crucial as it addresses the need for more accurate diagnostics in endemic regions, potentially reducing misdiagnosis and improving treatment efficacy. Roche's commitment to advancing diagnostic technology underscores its strategic focus on innovation as a key differentiator in the market.

In August  BD (US) expanded its point-of-care testing portfolio by introducing a new device specifically designed for malaria detection. This expansion is indicative of BD's strategy to enhance accessibility to rapid testing solutions, which is vital in controlling malaria outbreaks. By focusing on point-of-care solutions, BD is likely to strengthen its competitive position in a market that increasingly values speed and accuracy in diagnostics.

As of November  current trends in the malaria diagnostics market are heavily influenced by digitalization, sustainability, and the integration of artificial intelligence (AI) into diagnostic processes. Strategic alliances are becoming increasingly important, as they enable companies to pool resources and expertise, thereby enhancing innovation. The competitive landscape is shifting from traditional price-based competition to a focus on technological advancements and supply chain reliability. This evolution suggests that companies that prioritize innovation and strategic partnerships will likely emerge as leaders in the malaria diagnostics market.

## Recent News & Developments

The US [Malaria Diagnostics](../../../reports/malaria-diagnostics-market-6432) Market has seen significant developments recently, with companies like Hologic and Thermo Fisher Scientific focusing on enhancing their diagnostic capabilities amidst a rise in malaria cases linked to climate factors. In September 2023, Abbott launched a rapid malaria test aimed at improving detection rates in endemic regions within the US. Growth in market valuation is evident, as evidenced by Danaher's acquisition strategy aimed at broadening its diagnostic portfolio through innovations.

Grifols and BioRad Laboratories are exploring partnerships to enhance their diagnostics solutions, reflecting a trend toward collaborative efforts in technology advancement. Additionally, in July 2023, Roche announced the launch of a new diagnostic platform that enhances sensitivity and specificity for malaria detection. Furthermore, Meridian Bioscience reported a steady rise in revenue during 2022 due to increased demand for malaria diagnostic tests.

Current affairs also reflect a heightened emphasis on R&D investments targeted at malaria diagnostics, with agencies such as the Centers for Disease Control and Prevention emphasizing the need for more robust testing solutions in response to rising global malaria cases. These trends depict an evolving market landscape, driven by innovations and strategic collaborations among major companies.

## Report Scope

| MARKET SIZE 2024 | 7.05(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 7.49(USD Million) |
| MARKET SIZE 2035 | 13.71(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.23% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Roche (CH), Abbott (US), Siemens Healthineers (DE), BD (US), Cepheid (US), Hologic (US), Thermo Fisher Scientific (US), Diatheva (IT) |
| Segments Covered | Technology, End User, Product Type, Application |
| Key Market Opportunities | Integration of advanced molecular diagnostics enhances accuracy and speed in malaria detection. |
| Key Market Dynamics | Technological advancements drive innovation in malaria diagnostics, enhancing accuracy and speed of detection methods. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the market valuation of the US malaria diagnostics market in 2024?**
A: The market valuation was $7.05 Million in 2024.

**Q: What is the projected market valuation for the US malaria diagnostics market in 2035?**
A: The projected valuation for 2035 is $13.71 Million.

**Q: What is the expected CAGR for the US malaria diagnostics market during the forecast period 2025 - 2035?**
A: The expected CAGR during the forecast period is 6.23%.

**Q: Which technology segment is anticipated to show the highest growth in the US malaria diagnostics market?**
A: The Rapid Diagnostic Tests segment is expected to grow from $2.82 Million in 2024 to $5.38 Million by 2035.

**Q: How do the revenues from microscopy compare to those from polymerase chain reaction in the US malaria diagnostics market?**
A: Microscopy revenues were $1.05 Million in 2024, while polymerase chain reaction revenues were $1.26 Million.

**Q: What are the key end-user segments in the US malaria diagnostics market?**
A: Key end-user segments include Hospitals, Diagnostic Laboratories, Research Institutes, and Home Care Settings.

**Q: What was the revenue for test kits in the US malaria diagnostics market in 2024?**
A: The revenue for test kits was $2.82 Million in 2024.

**Q: Which company is a key player in the US malaria diagnostics market?**
A: Roche is one of the key players in the US malaria diagnostics market.

**Q: What is the expected revenue growth for reagents in the US malaria diagnostics market by 2035?**
A: Revenues for reagents are projected to increase from $2.11 Million in 2024 to $4.05 Million by 2035.

**Q: What applications are driving the US malaria diagnostics market?**
A: Applications driving the market include Clinical Diagnosis, Epidemiological Studies, and Drug Efficacy Studies.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-malaria-diagnostics-market-14640*